Follow the people · Insider
Kevin McCulloch
Kevin McCulloch files insider transactions with the SEC as an officer of Xeris Biopharma Holdings (XERS). We hold 4 disclosed purchases and sales filed since 2 August 2024, 3 of them in the last 90 days.
- Files forXERS
- Disclosed buys and sells4 in all, 3 in the last 90 days
- Last disclosure1 September 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 August 2024 — 1 September 2026Officer · Xeris Biopharma Holdings (XERS)36 Form 4 lines · source: SEC Form 4
Everything they disclosed
36 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 15,000 shares of Xeris Biopharma HoldingsSEC Form 41 September 2026Common Stock · traded 1 September 2026 · filed 1 September 2026
- had shares withheld for tax on 21,918 shares of Xeris Biopharma HoldingsSEC Form 421 August 2026Common Stock · traded 1 August 2026 · filed 21 August 2026
- ▼ sold on the open market 15,000 shares of Xeris Biopharma HoldingsSEC Form 44 August 2026Common Stock · traded 3 August 2026 · filed 4 August 2026
- ▼ sold on the open market 90,000 shares of Xeris Biopharma HoldingsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- exercised options over 48,894 shares of Xeris Biopharma HoldingsSEC Form 416 March 2026Common Stock · traded 12 March 2026 · filed 16 March 2026
- exercised options over 4 shares of Xeris Biopharma HoldingsSEC Form 416 March 2026Common Stock · traded 12 March 2026 · filed 16 March 2026
- exercised options over 48,894 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 416 March 2026Stock Option (Right to Buy) · traded 12 March 2026 · filed 16 March 2026
- exercised options over 48,894 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 416 March 2026Stock Option (Right to Buy) · traded 12 March 2026 · filed 16 March 2026
- exercised options over 4 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 416 March 2026Stock Option (Right to Buy) · traded 12 March 2026 · filed 16 March 2026
- exercised options over 4 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 416 March 2026Stock Option (Right to Buy) · traded 12 March 2026 · filed 16 March 2026
- exercised options over 48,894 shares of Xeris Biopharma HoldingsSEC Form 416 March 2026Common Stock · traded 12 March 2026 · filed 16 March 2026
- exercised options over 4 shares of Xeris Biopharma HoldingsSEC Form 416 March 2026Common Stock · traded 12 March 2026 · filed 16 March 2026
- was granted 168,463 shares of Xeris Biopharma HoldingsSEC Form 42 February 2026Common Stock · traded 30 January 2026 · filed 2 February 2026
- had shares withheld for tax on 68,454 shares of Xeris Biopharma HoldingsSEC Form 42 February 2026Common Stock · traded 31 January 2026 · filed 2 February 2026
- had shares withheld for tax on 30,289 shares of Xeris Biopharma HoldingsSEC Form 42 February 2026Common Stock · traded 31 January 2026 · filed 2 February 2026
- was granted 225,225 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 42 February 2026Stock Option (Right to Buy) · traded 30 January 2026 · filed 2 February 2026
- had shares withheld for tax on 27,319 shares of Xeris Biopharma HoldingsSEC Form 42 February 2026Common Stock · traded 31 January 2026 · filed 2 February 2026
- was granted 225,225 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 42 February 2026Stock Option (Right to Buy) · traded 30 January 2026 · filed 2 February 2026
- was granted 168,463 shares of Xeris Biopharma HoldingsSEC Form 42 February 2026Common Stock · traded 30 January 2026 · filed 2 February 2026
- had shares withheld for tax on 68,454 shares of Xeris Biopharma HoldingsSEC Form 42 February 2026Common Stock · traded 31 January 2026 · filed 2 February 2026
- had shares withheld for tax on 30,289 shares of Xeris Biopharma HoldingsSEC Form 42 February 2026Common Stock · traded 31 January 2026 · filed 2 February 2026
- had shares withheld for tax on 27,319 shares of Xeris Biopharma HoldingsSEC Form 42 February 2026Common Stock · traded 31 January 2026 · filed 2 February 2026
- ▼ sold on the open market 15,000 shares of Xeris Biopharma HoldingsSEC Form 49 January 2026Common Stock · traded 8 January 2026 · filed 9 January 2026
- ▼ sold on the open market 15,000 shares of Xeris Biopharma HoldingsSEC Form 49 January 2026Common Stock · traded 8 January 2026 · filed 9 January 2026
- had shares withheld for tax on 733 shares of Xeris Biopharma HoldingsSEC Form 43 October 2025Common Stock · traded 2 October 2025 · filed 3 October 2025
- acquired or disposed of, other 2,000 shares of Xeris Biopharma HoldingsSEC Form 415 September 2025Common Stock · traded 11 September 2025 · filed 15 September 2025
- had shares withheld for tax on 14,651 shares of Xeris Biopharma HoldingsSEC Form 44 August 2025Common Stock · traded 1 August 2025 · filed 4 August 2025
- ▲ bought on the open market 25,000 shares of Xeris Biopharma HoldingsSEC Form 416 June 2025Common Stock · traded 13 June 2025 · filed 16 June 2025
- had shares withheld for tax on 733 shares of Xeris Biopharma HoldingsSEC Form 43 April 2025Common Stock · traded 2 April 2025 · filed 3 April 2025
- was granted 500,000 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 43 February 2025Stock Appreciation Right · traded 31 January 2025 · filed 3 February 2025
- had shares withheld for tax on 29,300 shares of Xeris Biopharma HoldingsSEC Form 43 February 2025Common Stock · traded 31 January 2025 · filed 3 February 2025
- had shares withheld for tax on 48,834 shares of Xeris Biopharma HoldingsSEC Form 43 February 2025Common Stock · traded 31 January 2025 · filed 3 February 2025
- was granted 185,000 shares of Xeris Biopharma HoldingsSEC Form 43 February 2025Common Stock · traded 31 January 2025 · filed 3 February 2025
- had shares withheld for tax on 24,501 shares of Xeris Biopharma HoldingsSEC Form 47 January 2025Common Stock · traded 3 January 2025 · filed 7 January 2025
- was granted 200,000 shares of Xeris Biopharma Holdings (a derivative holding)SEC Form 42 August 2024Stock Appreciation Right · traded 1 August 2024 · filed 2 August 2024
- was granted 150,000 shares of Xeris Biopharma HoldingsSEC Form 42 August 2024Common Stock · traded 1 August 2024 · filed 2 August 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.